Show Summary Details
Page of

Strontium ranelate (SR) 

Strontium ranelate (SR)
Strontium ranelate (SR)

Rita Abdulkader

and Gavin Clunie

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 November 2020

Strontium is a bone-seeking agent with double the atomic weight of calcium.

Randomized controlled trials suggest that strontium ranelate (SR) is effective in the prevention of vertebral and non-vertebral fracture in post-menopausal osteoporosis.

The initial good safety profile of SR has been updated, given concerns about the risk of thrombosis and excess risk of cardiovascular disease.

After initiation of SR treatment, bone density increases quickly, 50% of which are related to strontium bone accumulation, but the use of dual X-ray absorptiometry scans in monitoring treatment is still impractical in practice.

SR appears to increase BMD, following cessation of bisphosphonate use, though fracture prevention and long-term safety, as a result of such ‘follow-on’ therapy, have not yet been shown.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.